col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


26 Results       Page 1

 [1] 
Elsevier: Toxicology Letters
  original article Date Title Authors   All Authors
1 [GO] 2025―Sep―08 P31-09 Pharmacological Safety Evaluation of a Plant-Derived SARS-CoV-2 Vaccine in Preclinical Models W.-J. Im, S.-J. Park, W. Kim, H. Kang, E.-J. Sohn, M.S. Jang, et al. (+2)
2 [GO] 2025―Sep―08 P31-08 Evaluation of Repeated-Dose Toxicity and Safety of a Plant-Derived SARS-CoV-2 S1 Vaccine in New Zealand White Rabbits W. Kim, S.-J. Park, M.-K. Cho, H. Kang, E.-J. Sohn, M.S. Jang, et al. (+3)
3 [GO] 2025―Sep―08 LP-16 Phytotherapeutic Potential of Urtica dioica: Antiviral Activity and Immunomodulatory Effects Against SARS-CoV-2 Y. Cetin, G. Akbas, J. Dursun, S. Aydinlik Sanlı
4 [GO] 2025―Sep―08 P18-105 Evaluation of Inhalation and Gastrointestinal Toxicity of Novel Benzoazepine Derivatives with Potential Therapeutic Effects for the Treatment of COVID-19 and Post-COVID Syndrome P. Pôbiš, K. Gabrišová, A.M. Palenčárová, M. Majekova, L. Kovacikova, S.A. Mahmood, et al. (+2)
5 [GO] 2025―Sep―08 S23-02 The evolving understanding of the risks and benefits of the new mRNA technologies in prevention of COVID-19 G. Quinn
6 [GO] 2025―Aug―18 Cytokine Profile and Early Immune Response to SARS-CoV-2 in Occupationally Lead-Exposed Individuals: A Cross-Sectional Study Marta Jeziorska, Sławomir Kasperczyk, Michał Słota, Jakub Jakubowski, Aleksandra Kasperczyk, Zenon P. Czuba, et al. (+5)
7 [GO] 2025―Feb―01 Evaluation of the causal effects of perfluorooctanesulfonate on COVID-19 and its associated mechanisms: Integrated Mendelian randomization and network toxicology analyses Wenting Tao, Liang Chen
8 [GO] 2024―Sep―02 P15-15 Unveiling the therapeutic potential of MSC-derived conditioned media and exosomes towards COVID-19-induced neurological sequelae C.M. Trigo, S.P. Camões, A.S. Serras, A.T. Matos, R. Vitorino, A.R. Vaz, et al. (+3)
9 [GO] 2024―Sep―02 P17-05 The T cell response to SARS-CoV-2 mRNA vaccine in adults with high exposure to perfluoroalkyl substances from Ronneby, Sweden A. Andersson, A. Lundgren, Y. Xu, C. Nielsen, C. Lindh, D. Pineda, et al. (+6)
10 [GO] 2024―Sep―02 P21-34 SARS-CoV-2 omicron infection aggravates lung fibrosis through IL6/ CSF/ RANTES activation and dysfunction of lipid metabolism in mice with PHMG-induced lung injury S. Jeon, Y.K. Kim, J.-H. Hwang, M.-S. Kim
11 [GO] 2024―Sep―02 P16-02 Subchronic intramuscular toxicity and immunogenicity study of a plant-based SARS-CoV-2 vaccine in Sprague-Dawley rats with a 4-week recovery period S.-J. Park, E.Y. Koo, H. Park, S.E. Min, B.-H. Choi, N. Kim, et al. (+3)
12 [GO] 2024―Jun―24 Epidemiological Samplings for long-term HBM-studies during a pandemic situation - Experiences and lessons-learned, the German Environmental Specimen Bank during the COVID-19 pandemic Martina Bartel-Steinbach, Till Weber, Markus Michel, Sylvia Wagner, Heiko Zimmermann, Marike Kolossa-Gehring, Dominik Lermen
13 [GO] 2023―Sep―06 P21-16: Preconditioning MSCs with IFN-γ as a promising therapeutic strategy towards COVID-19-induced neurological damage C.M. Trigo, S.P. Camões, A.S. Serras, M. Gava, R. Vitorino, A.R. Vaz, et al. (+3)
14 [GO] 2023―Sep―06 P17-31: Acute exposure to urban air ultrafine and coarse particles alters cellular response to SARS-CoV-2 infection in human olfactory mucosa cells from individuals with Alzheimer's disease M.A. Shahbaz, L. Mussalo, S. Kuivanen, J. Kalapudas, A.M. Koivisto, E. Penttilä, et al. (+7)
15 [GO] 2022―Sep―12 P03-06 The effectiveness of herbal combination as complementary treatment process in a patient with COVID-19 A. Ebadollahinatanzi, G. Arabrahmatipour
16 [GO] 2022―Sep―12 P22-10 Prevalence and outcome of Covid-19 in patients with substance abuse disorder presented to tertiary care hospital emergency department S.A. AlAbri, F. Al Majrafi
17 [GO] 2022―Sep―12 S-11-03 Accelerated timelines for non-clinical studies to support COVID-19 vaccine (AZD1222, ChAdOx1-nCov19) R. Stebbings
18 [GO] 2022―Sep―12 S-11-02 Regulatory considerations for non-clinical studies for COVID-19 vaccines: US FDA perspective C. Wrzesinski
19 [GO] 2022―Sep―12 P03-22 Evaluation of surgical stress impact over immune response against SARS-CoV-2. A pilot study T.K. Nikolouzakis, E. Vakonaki, M. Tzatzarakis, K. Lasithiotakis, E. Chryssos, A. Tsatsakis
20 [GO] 2021―Sep―24 Virus Response Measures in Case of Infection with a Previously Unknown Virus or COVID-19 in Employees at Research Facility T. Anzai, T. Matsuyama
21 [GO] 2021―Sep―24 COVID-19, health recovery by medicinal plants (health solutions): An overview A. Ebadollahinatanzi, G. Arabrahmatipour, M. Abedi
22 [GO] 2021―Sep―24 Specific treatments in the critically ill COVID-19 patients: benefits and toxicities B. Mégarbane
23 [GO] 2021―Sep―24 Rapid Development of the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Pilot Project to Monitor Adverse Events Reported in Association with COVID-19 Therapeutics P.M. Wax, K. Aldy, J. Brent
24 [GO] 2021―Sep―24 Brain Organoids to Study SARS-Cov-2 Infection of Developing CNS L. Smirnova, C.K. Bullen, H.T. Hogberg, A. Pekosz, W Bishai, T. Hartung
25 [GO] 2021―Sep―24 mRNA vaccines against SARS-CoV-2: review of non-clinical challenge studies and potential contagiosity in Non Human Primates M. Burbank, F. D’herbe, R. Soares, G. Louin, A. Richard, V. Salomon
26 [GO] 2021―Sep―24 Assessment of the skin sensitizing potential of pandemic-associated medical devices using the GARDskin Medical Device assay P. Mohlin, A. Forreryd, O. Larne, R.-M. Jenvert, H. Johansson
 [1] 

26 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.006 sec